BioSpace News Archive

EIP Pharma Inc. announced the oral presentation by academic investigators from the Amsterdam University Medical Center of neuroimaging results from a phase 2a clinical study in patients with early Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases 2023, which took place virtually and in person March 28 – April 1, 2023, in Gothenburg, Sweden.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company primarily focused on cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).

INOVIO announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan.

Semler Scientific, Inc., a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services 2024 Medicare Advantage and Part D Final Rate Announcement.

Rallybio Corporation announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis, which will take place in Montreal from June 24-28.

Scorpion Therapeutics, Inc. (“Scorpion”), a clinical-stage biotechnology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it has named STX-241 as its next development candidate.

VECT-HORUS, a biotechnology company that designs and develops vectors that facilitate the targeted delivery of therapeutic molecules and imaging agents, announced the appointment of Dr Jean-Manuel Péan as Chief Scientific Officer.

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open.

Abcuro, Inc. today announced initiation of a registrational Phase 2/3 study of ABC008 in inclusion body myositis (IBM).